Skip to content

Blog

Tag: Ligand Binding Assay

Multiplexed Cytokine Analysis in Drug Development

Cytokines are proteins released by activated cells that serve as soluble messengers binding to target cells through surface receptors, signaling functional responses. The nature of…

Read More

Is ISR Needed For Biomarker Assays?

Incurred sample reanalysis (ISR) is a well-established measure for the reproducibility of pharmacokinetic (PK) assays and commonly conducted in regulated studies. ISR was established in…

Read More

BioAgilytix Adds Extensive Capabilities with the Acquisition of MicroConstants and 360biolabs®

BioAgilytix, a leading global contract research organization focused on supporting its pharmaceutical and biotech partners in all stages of drug development, recently acquired MicroConstants and…

Read More

Cell and Gene Therapies Account for a Large Portion of the Therapeutics Market

Cell and gene therapies have gone through a growth spurt in the last decade. According to data from the Alliance for Regenerative Medicine (ARM), during…

Read More

CMC Requirements for Cell and Gene Therapy for IND Applications

The U.S. Food and Drug Administration (FDA) has issued Chemistry, Manufacturing, and Control (CMC) recommendations for Investigational New Drug (IND) applications for human investigational gene…

Read More

Answering Your Questions on Developing a Relative Potency Assay for an Anti-Influenza mAb

Dr. Jeff Patrick answers questions on how BioAgilytix translated a diagnostic virus neutralization method to a quantitative relative potency assay for an anti-viral antibody.

Read More

Bioanalytical Testing Under GMP: Assuring Biologic Safety & Efficacy via Impurities Assays

We discuss the need to put phase-appropriate methods in place to identify and quantify both process- and host-cell related impurities throughout the drug development process.

Read More

C-Path “Points to Consider Document” Clarifies Bioanalytical Assay Validation in Support of Clinical Biomarker Qualification

A contributing author to the Critical Path Institute (C-Path)’s “Points to Consider Document,” Dr. Afshin Safavi summarizes considerations outlined in the paper designed to establish…

Read More

To the Rescue: Applying a Novel Approach to Minimize False Positive ADA Assay Results

Target interference can cause false positive ADA assay results and stall out promising drugs. This could have been the case for one study involving an…

Read More

Ligand-Binding Assay Optimization, Part 1: Critical Attributes of Platforms Used

Consistent discussion and improvement upon the standard practices of bioanalytical laboratories is critical to improving the work we do supporting innovative biologics development in the…

Read More